PCM
MDGL icon

Penserra Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Penserra Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-954
Closed -$437K – 1112
2025
Q3 		$437K Buy
+954
New +$356K 0.01% 599
2021
Q4 		– Sell
-380
Closed -$30K – 1470
2021
Q3 		$30K Hold
380
– – ﹤0.01% 1180
2021
Q2 		$37K Buy
380
+15
+4% +$1.78K ﹤0.01% 1065
2021
Q1 		$42K Buy
365
+5
+1% +$583 ﹤0.01% 842
2020
Q4 		$40K Buy
+360
New +$44K ﹤0.01% 728

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Penserra Capital Management's MDGL Position: Q4 2025 in Review

Penserra Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2025, closing a stake of 954 shares — an estimated $437K sold.

Penserra Capital Management first reported a position in MDGL in Q4 2020 and held it in 5 quarters. The position peaked at $437K in Q3 2025. 387 funds tracked by Wall St. Rank hold MDGL as of Q4 2025.

  • Penserra Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Penserra Capital Management sold 954 Madrigal Pharmaceuticals shares in Q4 2025, an estimated $437K.
  • Penserra Capital Management first reported a position in Madrigal Pharmaceuticals in Q4 2020 and held it in 5 quarters.
  • Penserra Capital Management's Madrigal Pharmaceuticals position peaked at $437K in Q3 2025.
  • 387 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2025.

Based on Penserra Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.